论文部分内容阅读
[目的]了解和分析依达拉奉联合尿激酶治疗急性脑梗死的疗效。[方法]将收治的急性脑梗死67例作为实验组进行分析,急性脑梗死52例作为随机对照组。考察两组患者的神经功能缺损程度程度、疗效差异与不良反应。[结果]治疗一个疗程后,两组的SSS评分均显著低于治疗前(P﹤0.05);观察组的SSS评分显著低于对照组(P﹤0.05)。对照组显效率为42.3,有效率为71.2;实验组显效率为64.2,有效率为88.1。实验组的疗效优于对照组(P﹤0.05)。[结论]依达拉奉联合尿激酶是治疗ACI安全有效的方法,有广泛的应用前景。
[Objective] To understand and analyze the efficacy of edaravone combined with urokinase in the treatment of acute cerebral infarction. [Methods] 67 cases of acute cerebral infarction treated as experimental group were analyzed, 52 cases of acute cerebral infarction as a randomized controlled group. To investigate the degree of neurological deficit in both groups, differences in efficacy and adverse reactions. [Results] After one course of treatment, the SSS scores of both groups were significantly lower than those before treatment (P <0.05). The SSS scores of the observation group were significantly lower than those of the control group (P <0.05). In the control group, the effective rate was 42.3 and the effective rate was 71.2. The effective rate in the experimental group was 64.2 and the effective rate was 88.1. The efficacy of the experimental group was better than that of the control group (P <0.05). [Conclusion] Edaravone combined with urokinase is a safe and effective method for the treatment of ACI. It has a broad application prospect.